Effect of an aortic proteoglycan on platelet aggregation and thrombin time: plasma requirement and active moieties (39898).
D001011:Aorta / Q000378:metabolism*; D002810:Chondroitinases and Chondroitin Lyases / Q000494:pharmacology; D006025:Glycosaminoglycans / Q000494:pharmacology; D006487:Hemostasis / Q000187:drug effects*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D010206:Papain / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011479:Protamines / Q000494:pharmacology; D011509:Proteoglycans / Q000494:pharmacology*; D011517:Prothrombin Time
D006025:Glycosaminoglycans; D011479:Protamines; D011509:Proteoglycans; D006493:Heparin; D010206:Papain; D002810:Chondroitinases and Chondroitin Lyases